204 related articles for article (PubMed ID: 35050711)
21. Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
Lau-Min KS; Li Y; Eads JR; Mamtani R; Getz KD
Cancer; 2022 May; 128(9):1853-1862. PubMed ID: 35119688
[TBL] [Abstract][Full Text] [Related]
22. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
23. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
Maron SB; Moya S; Morano F; Emmett MJ; Chou JF; Sabwa S; Walch H; Peterson B; Schrock AB; Zhang L; Janjigian YY; Chalasani S; Ku GY; Disel U; Enzinger P; Uboha N; Kato S; Yoshino T; Shitara K; Nakamura Y; Saeed A; Kasi PM; Chao J; Lee J; Capanu M; Wainberg Z; Petty R; Pietrantonio F; Klempner SJ; Catenacci DVT
J Clin Oncol; 2022 Aug; 40(22):2458-2467. PubMed ID: 35349370
[TBL] [Abstract][Full Text] [Related]
24. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
25. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
[TBL] [Abstract][Full Text] [Related]
26. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
27. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
[TBL] [Abstract][Full Text] [Related]
28. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
29. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
[TBL] [Abstract][Full Text] [Related]
30. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
Abdelhakeem A; Wang X; Rogers JE; Trail A; Zhao M; Blum-Murphy M; Estrella JS; Ajani JA
Oncology; 2020; 98(12):884-888. PubMed ID: 32998149
[TBL] [Abstract][Full Text] [Related]
33. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
34. Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice.
Lau-Min KS; Li Y; Eads JR; Wang X; Meropol NJ; Mamtani R; Getz KD
Cancer; 2021 Jul; 127(14):2562-2570. PubMed ID: 33730386
[TBL] [Abstract][Full Text] [Related]
35. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
36. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
37. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
38. Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study.
Birkness JE; Spada NG; Miller C; Luketich JD; Nason KS; Sun W; Davison JM
Genes Chromosomes Cancer; 2018 Jan; 57(1):28-34. PubMed ID: 28913947
[TBL] [Abstract][Full Text] [Related]
39. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
